secwatch / observer
8-K filed July 27, 2023, 7:59 PM ET ticker NEOG CIK 0000711377
earnings confidence high sentiment neutral materiality 0.60

Neogen Q4 revenue up 72.6% to $241.8M; net income $5.6M; FY2024 guidance issued

NEOGEN CORP

2023-FY EPS reported -$0.12 revenue$822,447,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEOGEN CORP reported fiscal 2023 fourth quarter ended May 31, 2023 results: revenue $241.8 million, net income $5.6 million, EPS $0.03 per diluted share.

Period
fiscal 2023 fourth quarter ended May 31, 2023
Revenue
$241.8 million
Net income
$5.6 million
EPS
$0.03 per diluted share
Result
reported results
Exact text from the filing
Neogen Announces Fourth-Quarter 2023 Results • Revenue of $241.8 million, an increase of 72.6% over the prior-year quarter. • Net income of $5.6 million; $0.03 per diluted share.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEOGEN CORP reported fiscal year ended May 31, 2023 results: revenue $822.4 million, net income a loss of $22.9 million, EPS $0.12 per diluted share.

Period
fiscal year ended May 31, 2023
Revenue
$822.4 million
Net income
a loss of $22.9 million
EPS
$0.12 per diluted share
Result
reported results
Exact text from the filing
fourth quarter marked the 124th of the past 130 quarters that Neogen reported revenue increases compared to the same quarter in the prior year. Revenues for the full year were $822.4 million, an increase of 56.0% compared to $527.2 million in the prior year. Core revenue growth was 4.0% and acquisitions contributed 54.5%, while foreign currency was a headwind of
View on SEC.gov

Browse all earnings releases →

NEOGEN CORP filing history →

Source: SEC EDGAR
accession 0000950170-23-034944
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.